Prognostic models: clinical impact now within reach

Affiliations

¹ Data Science, Pharma Research and Development, Roche Innovation Center Munich, Munich, Germany. Electronic address: anna.bauer-mehren@roche.com.
² Early Clinical Development Oncology, Pharma Research and Development, Roche Innovation Center Munich, Munich, Germany.

Free article

Comment

A Bauer-Mehren et al. Ann Oncol. 2021 Jan.

Free article

. 2021 Jan;32(1):123-124.

doi: 10.1016/j.annonc.2020.10.467. Epub 2020 Oct 17.

¹ Data Science, Pharma Research and Development, Roche Innovation Center Munich, Munich, Germany. Electronic address: anna.bauer-mehren@roche.com.
² Early Clinical Development Oncology, Pharma Research and Development, Roche Innovation Center Munich, Munich, Germany.

No abstract available

Conflict of interest statement

Disclosure ABM and DR are employees of Roche.

An enhanced prognostic score for overall survival of patients with cancer derived from a large real-world cohort.
Becker T, Weberpals J, Jegg AM, So WV, Fischer A, Weisser M, Schmich F, Rüttinger D, Bauer-Mehren A. Becker T, et al. Ann Oncol. 2020 Nov;31(11):1561-1568. doi: 10.1016/j.annonc.2020.07.013. Epub 2020 Jul 31. Ann Oncol. 2020. PMID: 32739409
Pan-cancer prognostic models of clinical outcomes: statistical exercise or clinical tools?
Halabi S. Halabi S. Ann Oncol. 2020 Nov;31(11):1427-1429. doi: 10.1016/j.annonc.2020.08.2233. Epub 2020 Sep 3. Ann Oncol. 2020. PMID: 32891792 No abstract available.